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Spontaneous production of inﬂ  ammatory  cytokines, 
along with tissue-destructive enzymes, is one of the 
unique characteristics of rheumatoid arthritis (RA) syno-
vial tissue. Th   e discovery of this phenomenon by Brennan 
and colleagues in 1989 has led to the understanding of 
the central role of tumor necrosis factor-alpha (TNFα) 
and its position upstream of interleukin-1 (IL-1) and IL-6 
in RA. As major mediators of joint inﬂ  ammation and 
destruction, these cytokines have become targets of novel 
therapeutics in recent years; however, the factors driving 
their production remain largely unknown. In the previous 
issue of Arthritis Research & Th  erapy, Nic An Ultaigh and 
colleagues [1] reported that Toll-like receptor 2 (TLR2) 
mediates spontaneous cytokine release from RA ex vivo
synovial explant cultures.
TLRs are a family of pattern recognition receptors 
evolved to recognize conserved microbe-associated 
mole  cu  lar patterns. Signal transduction through TLRs 
controls the expression of a number of proinﬂ  ammatory 
cytokines, including TNFα, IL-1 and IL-6, chemokines 
such as IL-8, and matrix metalloproteinases, factors that 
are spontaneously and chronically produced by disso-
ciated RA synovial mononuclear cell cultures [2,3]. Some 
TLRs such as TLR2, TLR3, and TLR4 can be activated by 
endogenous ‘danger’ molecules associated with inﬂ  am-
ma  tion and tissue destruction, and many of these 
molecules have been found in joints and serum of 
patients with RA and show a positive correlation with 
disease activity scores [4,5]. As TLR-mediated inﬂ  amma-
tory response may induce further tissue damage and 
promote the generation of additional endogenous 
ligands, it has been hypothesized that TLRs can engender 
a self-sustaining inﬂ   ammatory loop responsible for 
chronic progression of RA [6,7].
Using synovial explant cultures in which tissue 
structure and complexity are preserved, Nic An Ultaigh 
and colleagues [1] introduced TLR2 as a driving force 
behind spontaneous cytokine production in RA. First, 
the authors showed that a monoclonal antibody against 
TLR2 can inhibit, as expected, cytokine production 
induced by a TLR2 agonist in RA peripheral blood and 
synovial ﬂ  uid mononuclear cells. Importantly, this anti-
body signiﬁ  cantly suppressed the spontaneous release of 
TNFα, interferon-gamma (IFN-γ), and IL-1β and IL-8 by 
synovial tissue explants to an extent comparable to that 
of the TNF inhibitor adalimumab. Th  ese observations 
suggest the relevance of TLR2 in RA pathogenesis.
A growing body of evidence links TLR to spontaneous 
cytokine production by RA synovium. Besides enhanced 
expression of TLR2, those of TLR3, TLR4, and TLR7 in 
RA synovial tissue have been demonstrated before [4]. 
TLR4 has previously been found to drive spontaneous 
production of TNFα, IL-1β, and IL-10 by intact RA 
synovial tissue explants [8]. In addition, TLR4 contributes 
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and IL-17 production and promotes severe autoimmune 
sponta  neous arthritis in mice [8]. Along these lines, 
TLR4 blockade suppresses joint inﬂ  ammation  and 
destruc  tion in experimental arthritis, even during the 
established phase [9].
Spontaneous production of proinﬂ  ammatory cytokines 
and matrix metalloproteinases by RA synovial membrane 
cells can also be inhibited by overexpression of the 
dominant-negative form of MyD88 adaptor-like (Mal), an 
adaptor molecule speciﬁ  cally involved in TLR4 signaling 
and recently reported not to be essential for TLR2 
signaling [10,11]. Furthermore, TNFα production by RA 
synovial membrane cells could be blocked by imiquimod 
and the serotonin receptor antagonist mianserin, 
compounds suggested to inhibit TLR8 [12].
So far, the only in vivo evidence supporting TLR 
involve  ment in the vicious inﬂ  ammatory cycle in patients 
comes from a humanized model in which intact RA 
synovial explants were transplanted into severe-
combined immunodeﬁ  cient (SCID) mice. In this model, 
speciﬁ   c blockade of TLR4 markedly suppressed the 
spontaneous cytokine production and the severity of 
inﬂ  am  mation in the transplants to the same extent as 
adalimu  mab [13]. A head-to-head comparison of diﬀ  er-
ent TLRs in the valuable ex vivo model used by Nic An 
Ultaigh and colleagues and in the humanized RA-SCID 
model will help clarify their relative contributions to the 
vicious inﬂ  ammatory loop in RA.
Of note, the studies mentioned above all used relatively 
small (≤12) numbers of patients. From a clinical per  spec-
tive, however, it is important to consider the substantial 
heterogeneity among patients with RA. Microarray 
analysis of RA synovial tissues has revealed a noteworthy 
subdivision of patients, with one group having abundant 
expression of genes involved in adaptive immune 
response and another group expressing stromal cell-
related gene clusters with a tissue remodeling signature 
[14]. Th   e presence of an adaptive immune response is of 
high relevance in the case of TLR2, for which expression 
on regulatory T cells (Tregs) and a direct role in Treg 
proliferation and function have been reported [15]. In the 
autoimmune T cell-mediated arthritis that develops as a 
result of IL-1 receptor antagonist deﬁ  ciency,  TLR2 
protects mice from severe arthritis by controling Treg 
function and by counteracting the production of IFNγ 
and IL-17 [8]. Th  is implies that TLR2 blockade might 
have detrimental eﬀ  ects on restraining autoimmunity in 
a subset of patients. Finally, our unpublished observations 
indicate TLR2 as a negative regulator of Fcγ receptor 
response in macrophages, a function with important 
consequences in conditions in which immune complexes 
are present. In fact, the diverse pro- and anti-inﬂ  am-
matory functions of TLR2 may imply a dual role in 
arthritis, depending on the cells and the processes 
involved. However, the unambigu  ous proinﬂ  ammatory 
function of TLR4 appears to provide a solid therapeutic 
target with consistent beneﬁ  t.
In conclusion, the report by Nic An Ultaigh and 
colleagues supports the recently introduced concept of 
the involvement of TLRs in perpetuation of the chronic 
inﬂ  ammatory loop in RA in which endogenous ligands 
serve as triggers. Unraveling the divergent functions of 
these receptors and their relative roles in subpopulations 
of patients with RA is just the dawn of TLR-targeted 
therapy.
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